Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566447 · ClinicalTrials.gov registry record
"Solana™ Trichomonas Assay Field Study"
A clinical trial of Trichomonas Vaginalis, sponsored by Quidel Corporation.
- Completed
- Registry status
- 750
- Enrollment target
- 4
- Study locations
NCT02566447: Completed study of Trichomonas Vaginalis, sponsored by Quidel Corporation.
NCT02566447 is a study of Trichomonas Vaginalis that has completed, run by Quidel Corporation. The registered enrollment target is 750 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566447, a study of Trichomonas Vaginalis, has completed, sponsored by Quidel Corporation.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
- 4
- Study locations
Study Summary
The Solana® Trichomonas Assay is an in vitro qualitative nucleic acid amplification test for the detection of Trichomonas vaginalis to aid in the diagnosis of trichomoniasis using the Helicase-Dependent Amplification (HDA) technology and the Solana instrument.
Primary Outcome
Testing results will be received by testing site for current FDA cleared tests
Conditions Studied
Interventions
- DEVICE Solana Trichomonas Assay Testing
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
Maryland
- Johns Hopkins University School of Medicine - Baltimore
North Carolina
- University of North Carolina, Div. of Infectious Diseases - Chapel Hill
Washington
- University of Washington in Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2016-08-15 |
What the finished NCT02566447 record still lists
NCT02566447 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Trichomonas Vaginalis appearing as the primary indexed condition, and to 1 intervention - of which Solana Trichomonas Assay Testing is the first listed.
NCT02566447 reports a single indexed study location in Alabama, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02566447 about?
NCT02566447 is a clinical study titled ""Solana™ Trichomonas Assay Field Study"". The Solana® Trichomonas Assay is an in vitro qualitative nucleic acid amplification test for the detection of Trichomonas vaginalis to aid in the diagnosis of trichomoniasis using the Helicase-Dependent Amplification (HDA) technology and the Solana instrument.
What is the current status of trial NCT02566447?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2015-10-15. Estimated completion is 2016-08-15.
What conditions does trial NCT02566447 study?
This clinical trial studies the following conditions: Trichomonas Vaginalis.
What interventions are being tested in trial NCT02566447?
The interventions under investigation include: Solana Trichomonas Assay Testing (DEVICE).
Who is sponsoring clinical trial NCT02566447?
This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02566447 being conducted?
This trial has 4 study locations across Alabama, Maryland, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trichomonas Vaginalis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI